A new experimental drug called GLP-1-GIP-Lani, developed to tackle obesity and insulin resistance, showed striking benefits in early mouse studies by combining incretin hormones with PPAR activity to hit multiple metabolic targets at once; the work from the Institute for Diabetes and Obesity at Helmholtz Munich suggests stronger weight and blood sugar effects than current GLP-1 therapies while keeping side effects comparable in the animal models. The compound is being described as a quintuple agonist because it engages five receptor systems, and researchers say the design lets the PPAR component ride along with the incretin piece to act inside target cells. Laboratory results point to lower food intake, reduced fat mass and improved insulin-related markers in mice, but human testing is not yet underway.
The team led by Professor Timo D. Muller tested GLP-1-GIP-Lani in a variety of mouse models that included diabetes-induced obesity, insulin resistance and genetic obesity, and saw benefits beyond GLP-1 and GIP given alone. The drug fuses GLP-1 and GIP, hormones that help control appetite and blood sugar, with a PPAR element that can influence insulin sensitivity, inflammation, fat metabolism and liver function. In those preclinical tests the compound lowered body weight, food intake and markers of metabolic dysfunction while outperforming semaglutide in key measures.
Researchers call the molecule a quintuple agonist because it targets five receptor systems at once, a multitarget approach meant to treat obesity from several angles instead of just suppressing appetite. Muller described the drug as a “Trojan horse”: the incretin component — hormones that help regulate blood sugar and appetite — allows it to enter target cells, and once inside, the PPAR “cargo” activates to help the body better use insulin, process fat and reduce inflammation. That design is intended to concentrate the PPAR effect where it matters and avoid systemic exposure at high doses.
One practical upside the team emphasizes is dose efficiency: packing the PPAR activity into the incretin carrier means the second component does not need a high systemic dose to work, which could reduce off-target effects and tolerability problems seen with larger systemic doses. The animal data showed improvements in glucose handling and reduced adiposity without worsening typical gastrointestinal complaints compared with existing GLP-1 therapies. Side effect profiles in the mice were reported as similar to current treatments, which is an encouraging sign for development but far from a guarantee in humans.
“A major advantage is the amount,” Muller said. “Because the second component is not administered separately and systemically, but ‘travels along’ with the incretin part, it can be used at a dose that is orders of magnitude lower.” That quote captures the team’s strategy: leverage the incretin receptors to smuggle a metabolic booster into the same tissues that already respond to GLP-1 and GIP. If that delivery works the same way in people, it could let researchers dial up metabolic effects without proportionally increasing side effects.
Clinicians watching the work called it an intriguing step. Dr. Peter Balazs, MD, a hormone and weight-loss specialist practicing in New York and New Jersey, said the drug is designed to target obesity and insulin resistance “at multiple key sites simultaneously, including the brain, pancreas and metabolic tissues.” He added that this is different from merely escalating doses of existing medicines and that combining appetite suppression with direct metabolic changes could offer more durable results.
Balazs also noted the dual nature of the approach: “Current GLP-1 medications are highly effective appetite suppressants, while this quintuple agonist seems to function both as an ‘appetite brake’ and a metabolic engine,” he added. He pointed out that, beyond slowing appetite and gastric emptying, the compound “appears to do all of the above” while also “directly improving insulin sensitivity in the liver and muscle, reducing inflammation in adipose tissue and remodeling lipid metabolism,” the expert confirmed. “The result may be greater weight loss through a combination of caloric restriction, enhanced fat oxidation and potentially increased central energy expenditure,” Balazs said.
That promise comes with important caveats: the findings are preclinical and the studies were short-term, so jumping to conclusions would be premature. Although the mouse results offer a clear signal that the mechanism is worth exploring, there is no human safety or efficacy data yet and the drug cannot be recommended for clinical use. “Additionally, it was conducted over a relatively short period of time, so we cannot draw conclusions about long-term effects,” he added.
